Activity of Ceftolozane/Tazobactam Against Gram-Negative Rods of the Family Enterobacteriaceae and Pseudomonas Spp. Isolated from Onco-Hematological Patients Hospitalized in a Clinical Hospital in Poland

Abstract

BackgroundThe most common etiological agents of infections in onco-hematological patients are Gram-negative rods resistant to many antimicrobials, including carbapenems. Recently, ceftolozane combined with tazobactam became a novel therapeutic option. The aim of the present study was to analyze the susceptibility to ceftolozane/tazobactam of the clinical strains of these bacteria.Material/MethodsMaterial comprised rectal swabs, urine, and bronchoalveolar lavage fluid obtained from onco-hematological patients hospitalized in a clinical hospital (1050 beds) in Poland. Identification of the isolated bacteria was done by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) using the MALDI Biotyper (Bruker). Ceftolozane/tazobactam susceptibility of the isolates was assessed using antimicrobial gradient strips (E-test, BioMérieux). Antimicrobial susceptibility testing and interpretation of the results was done according to the current recommendations of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).ResultsIn total, 281 rectal swabs and 116 urine samples were tested for the presence of Gram-negative rods producing ESBL, and 531 rectal swabs and 8 bronchoalveolar lavage fluid samples were tested for the presence of Gram-negative rods resistant to carbapenems. In the analyzed period, 69 non-repetitive strains of bacteria were isolated that were in the spectrum of activity of ceftolozane/tazobactam. Among 44 clinical strains of ESBL(+) Enterobacteriaceae rods, 76% were susceptible to ceftolozane/tazobactam. All 9 strains of non-carbapenemase-producing P. aeruginosa resistant or with decreased susceptibility to carbapenems were susceptible to ceftolozane/tazobactam.ConclusionsCeftolozane/tazobactam may be an option in the therapy of infections caused by ESBL(+) strains of Enterobacteriaceae as well as non-carbapenemase-producing carbapenem-resistant strains of P. aeruginosa.

Activity of ceftolozane/tazobactam against commonly encountered antimicrobial resistant Gram-negative bacteria in Lebanon

“…The 96% C/T susceptibility rates among our non-MDR P. aeruginosa isolates were close to the high rates reported from other countries; e.g. 87% from Latin America, 95-100% from Germany, Poland, and USA [8,[16][17][18], and higher than those susceptibility rates reported from India (17-33%) [19]. However, the MDR P. aeruginosa isolates in our study showed low susceptibility rates to C/T (43%).…”

Infections Due to Carbapenem-Resistant Bacteria in Patients With Hematologic Malignancies

“…Cefiderocol (S-649266), a novel siderophore cephalosporin, was stable against relevant carbapenemases, including MBL, KPC, and OXA-48-group carbapenemases. Ceftolozan-tazobactam could be a therapeutic option in non-carbapenemase-producing CR GN strains in HM patients (Saran et al, 2019); Non-β lactam antibiotics, plazomicin and eravacycline, also represent potential options for the treatment of CR GN-bacterial infections. Plazomicin is a new generation aminoglycoside with increased in vitro activity against KPC-producing bacteria, but with a limited activity against the NDM group of CR bacteria, and is currently recommended to treat urinary tract infections, but not BSI (Cloutier et al, 2017;Connolly et al, 2018).…”

Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections

“…In the study conducted by Saran et al, CEF-TAZ activity was investigated in the case of 60 Enterobacteriaceae strains isolated from samples obtained from hematological patients in Poland. The results demonstrated that this combination could be a good option in treating CRE infections [ 114 ]. Castanheira et al evaluated the activity of CEF-TAZ against 2362 Enterobacteriaceae isolates obtained from respiratory tract specimens from patients hospitalized in the United States during 2013 to 2015.…”